Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
ApexOnco Front Page
Recent articles
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
A just revealed phase 3 trial will apparently pit a fixed-dose combo head to head against Opdualag.
For now, the group is sticking with what it knows ahead of a big year in lymphoma.
Despite magrolimab’s latest flop, efforts to target CD47 continue.
The latest clinical study listings reveal KRAS-targeting projects, ADCs and others starting phase 1.
Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.
Pelabresib's partial win at ASH was enough to persuade Novartis to pull the acquisition trigger.